International Stem Cell Corporation (OTCBB: ISCO)
https://smallcapvoice.com/blog/wp-content/uploads/isco-8-16-12.mp3

Dr. Simon Craw, Executive Vice President of International Stem Cell Corporation (OTCBB: ISCO), called into SmallCapVoice.com to go over the ISCO’s business model, market and recent news. International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells …

Continue Reading